


## CLAIMS

1. A compound of formula (I)



- 5 R represents halogen, C<sub>1-4</sub> alkyl, cyano, C<sub>1-4</sub> alkoxy, trifluoromethyl or trifluoromethoxy;  
 R<sub>1</sub> represents hydrogen, halogen, C<sub>3-7</sub>cycloalkyl, hydroxy, nitro, cyano or C<sub>1-4</sub> alkyl optionally substituted by halogen, cyano or C<sub>1-4</sub> alkoxy;  
 R<sub>2</sub> represents hydrogen or C<sub>1-4</sub> alkyl;  
 R<sub>3</sub> and R<sub>4</sub> independently represent hydrogen, cyano, C<sub>1-4</sub> alkyl or R<sub>3</sub> together with R<sub>4</sub>  
 10 represents C<sub>3-7</sub> cycloalkyl;  
 R<sub>5</sub> represents trifluoromethyl, S(O)<sub>t</sub> C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, trifluoromethoxy, halogen or cyano;  
 R<sub>6</sub> represents hydrogen or (CH<sub>2</sub>)<sub>r</sub>R<sub>7</sub>;  
 R<sub>7</sub> represents hydrogen, C<sub>3-7</sub> cycloalkyl, NH(C<sub>1-4</sub>alkylOC<sub>1-4</sub>alkoxy), NH(C<sub>1-4</sub>alkyl),  
 15 N(C<sub>1-4</sub>alkyl)<sub>2</sub>, OC(O)NR<sub>9</sub>R<sub>8</sub>, NR<sub>8</sub>C(O)NR<sub>9</sub> or C(O)NR<sub>9</sub>R<sub>8</sub>;  
 R<sub>9</sub> and R<sub>8</sub> independently represent hydrogen, C<sub>1-4</sub> alkyl or C<sub>3-7</sub> cycloalkyl;  
 m represents zero or an integer from 1 to 4;  
 n represents 1 or 2;  
 p is zero or an integer from 1 to 3;  
 20 q is an integer from 1 to 3;  
 r is an integer from 1 to 4;  
 t is 0, 1 or 2;  
 provided that when m is 0, p is 2, q, r and n represent 1, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>7</sub> are hydrogen and R is chlorine, R<sub>5</sub> is not iodine;  
 25 and pharmaceutically acceptable salts and solvates thereof.

2 A compound as claimed in claim 1 wherein R is halogen (e.g. fluorine or chlorine), cyano, trifluoromethyl or a C<sub>1-4</sub> alkyl (e.g. methyl) group and p is 0 or an integer from 1 to 2.

3. A compound as claimed in claims 1 or 2 wherein  $R_5$  is trifluoromethyl, cyano, methyl or halogen and  $q$  is an integer from 1 to 2.
4. A compound as claimed in any claims 1 to 3 wherein  $R_6$  is hydrogen or  $(CH_2)_r R_7$  in which  $r$  is 1 or 2 and  $R_7$  is hydrogen, cyclopropyl,  $C(O)N(C_{1-4} \text{ alkyl})_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$  or  $C_{1-4}$  alkoxy.
5. A compound as claimed in any claims 1 to 4 wherein  $R$  is  $C_{1-4}$  alkyl, halogen (i.e. chlorine or fluorine), trifluoromethyl or cyano;  $R_1$  is hydrogen, methyl, ethyl or halogen (e.g. fluorine),  $R_2$  is a methyl or hydrogen,  $R_3$  and  $R_4$  are independently hydrogen or methyl,  $R_5$  is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine,  $R_6$  hydrogen, methyl, ethyl methylcyclopropyl  $(CH_2)_2OCH_3$  or  $CH_2C(O)N(CH_3)_2$ ,  $p$  is 0 or an integer from 1 to 2,  $m$  is 0 or 1,  $n$  is 1 or 2,  $q$  is 1 or 2.
6. A compound as claimed in any claims 1 to 5 wherein  $m$  is 1.
7. A compound selected from:
- N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide ;
- 4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
- 4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;
- N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
- N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

- N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
- N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-
- 5 acetamide;
- N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;
- N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;
- N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-
- 10 acetamide;
- N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-
- acetamide;
- N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-
- 15 N-methyl-acetamide;
- N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-
- acetamide;
- N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-
- 20 acetamide;
- N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-
- acetamide;
- N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-
- acetamide;
- N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;
- 25 N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-
- acetamide;
- N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-
- acetamide;
- N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-
- 30 acetamide;
- N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-[2-(methyloxy)ethyl]-4-
- piperidinyl]-*N*-methylacetamide;
- N*-[1-(3,5-Bis(trifluoromethyl)phenyl)ethyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-
- methylacetamide;
- 35 *N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-
- methylacetamide;

- N*-[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;  
*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 5 *N*-[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidiny]acetamide;  
*N*-[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidiny]acetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 10 *N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidiny]acetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidiny]acetamide;  
*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 15 *N*-[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;  
*N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidiny]-*N*-methylacetamide;
- 20 *N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;  
*N*-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-*N*-methylacetamide ;  
*N*-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;
- 25 2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidiny]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;  
2-[4-{2-[[3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(4-fluorophenyl)-1-piperidiny]-*N,N*-dimethylacetamide;
- 30 *N*-[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidiny]-*N*-methylacetamide;  
*N*-[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;  
*N*-[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
- 35 *N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

- N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
- N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidiny]-*N*-methylacetamide;
- 5 *N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-[3-(trifluoromethyl)phenyl]-4-piperidiny]acetamide;
- N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidiny]acetamide;
- 10 *N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 15 *N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 2- [4-(3-Chlorophenyl)-4-piperidiny]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
- 20 *N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidiny]-*N*-methylacetamide ;
- 25 *N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-*N*-methylacetamide;
- N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;
- 30 2-[4-(3-Chlorophenyl)-4-piperidiny]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
- 2-[4-(3-Chlorophenyl)-1-methyl-4-piperidiny]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
- 2-[4-(3-Chlorophenyl)-4-piperidiny]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;
- 35 2-[4-(3-Chlorophenyl)-1-methyl-4-piperidiny]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;
- 2-[4-(3-Chlorophenyl)-4-piperidiny]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidiny]-*N*-methylacetamide;

5 *N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide ;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidiny]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;

10 *N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidiny]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidiny]-*N*-methylacetamide;

2-[4-(4-Cyanophenyl)-4-piperidiny]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

15 diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts (e.g. hydrochloride) thereof .

8 A compound selected from

[*N*-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-  
20 acetamide;

*N*-[1-(*S*)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;

*N*-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide (enantiomer 1);


25 *N*-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-*N*-methyl-acetamide (enantiomer 1);

*N*-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide (enantiomer 1);


and pharmaceutically acceptable salts thereof (e.g. hydrochloride).

30

9. A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R<sub>6</sub> is a nitrogen protecting group or (CH<sub>2</sub>)<sub>r</sub>R<sub>7</sub> , with amine (III)



wherein  $R_2$  is hydrogen,  $C_{1-4}$  alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group; or a process B for the preparation of a compound of formula(I) wherein  $R_2$  is  $C_{1-4}$  alkyl which comprises the reaction of a compound of formula(Ia), with  $(C_{1-4} \text{ alkyl})L$  wherein L is a suitable leaving group selected from iodine, bromine.



10. A compound as claimed in any claims 1 to 8 for use in therapy.

11. The use of a compound as claimed in any claims 1 to 8 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

12. The use of a compound as claimed in any claims 1 to 8 in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

13. A pharmaceutical composition comprising a compound as claimed in any claims 1 to 8 in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other

neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) as claimed in any claims 1 to 8.

5

10